Boehringer Ingelheim Venture Fund Overview
- Investor Type
-
Venture Capital
- Status
-
Active
- Professionals
-
14
- Investments
-
106
- Portfolio
-
41
- Exits
-
23
Boehringer Ingelheim Venture Fund General Information
Company Description
Founded in 2010, Boehringer Ingelheim Venture Fund is a corporate venture capital arm of Boehringer Ingelheim based in Ingelheim am Rhein, Germany. The seeks prefers to invest in companies operating in digital health, immune-oncology, regenerative medicine, and other technology sectors.
Business Details
Year Founded
Investor Status
Primary Investor Type
Corporate Office
- Binger Straße 173
- 55216 Ingelheim am Rhein
- Germany
Boehringer Ingelheim Venture Fund Investments (106)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Company Stage | Lead Partner |
|---|---|---|---|---|---|---|
| EvlaBio | 07-Jul-2025 | Seed Round | Biotechnology | Generating Revenue | ||
| Nuevocor | 06-May-2025 | Biotechnology | Pre-Clinical Trials | |||
| HepaRegenix | 15-Apr-2025 | Drug Discovery | Generating Revenue | |||
| ArrePath | 26-Mar-2025 | Drug Discovery | Generating Revenue | |||
| Brainomix | 10-Mar-2025 | Diagnostic Equipment | Generating Revenue | |||
| Refoxy Pharma | 04-Dec-2024 | Drug Discovery | Pre-Clinical Trials | |||
| Aignostics | 29-Oct-2024 | Decision/Risk Analysis | Generating Revenue | |||
| Synthetica (China) | 26-Jul-2024 | Biotechnology | Pre-Clinical Trials | |||
| glucura | 17-Jul-2024 | Later Stage VC | Other Healthcare Technology Systems | Generating Revenue | ||
| Tacalyx | 11-Jun-2024 | Seed Round | Drug Discovery | Pre-Clinical Trials |
Boehringer Ingelheim Venture Fund Exits (23)
| Company Name | Exit Date | Exit Type | Exit Size |
|---|---|---|---|
| TigaTx | 07-Apr-2025 | Merger/Acquisition | |
| Dirico | 06-Dec-2024 | ||
| Cardior | 25-Mar-2024 | ||
| Metabomed | 08-Feb-2024 | ||
| Delonix Bioworks | 31-Dec-2023 | ||
| T3 Pharmaceuticals | 22-Nov-2023 | ||
| Aelin Therapeutics | 07-Jul-2023 | ||
| Anagenesis Biotechnologies | 05-Dec-2022 | ||
| OncoMyx Therapeutics | 01-Jul-2022 | Out of Business | |
| Abexxa Biologics | 21-Sep-2021 | Merger/Acquisition |
Boehringer Ingelheim Venture Fund Investments by Industry, Year, and Region
Investments by Industry
Investments by Year
Investments by Region
Boehringer Ingelheim Venture Fund Co-Investors (148)
| Name | With | Exits | Lead Partner | Series | Industry |
|---|---|---|---|---|---|
| High-Tech Gründerfonds | 8 |
|
|
||
| Kurma Partners |
|
|
|||
| Korea Investment Partners |
|
|
|||
| NRW.Bank |
|
|
|||
| Wellington Partners |
|
|
Boehringer Ingelheim Venture Fund FAQs
-
What is Boehringer Ingelheim Venture Fund?
Founded in 2010, Boehringer Ingelheim Venture Fund is a corporate venture capital arm of Boehringer Ingelheim based in Ingelheim am Rhein, Germany.
-
When was Boehringer Ingelheim Venture Fund founded?
Boehringer Ingelheim Venture Fund was founded in 2010.
-
Where is Boehringer Ingelheim Venture Fund headquartered?
Boehringer Ingelheim Venture Fund is headquartered in Ingelheim am Rhein, Germany.
-
What is Boehringer Ingelheim Venture Fund's total asset value?
Boehringer Ingelheim Venture Fund has around in total assets under management.
-
How many investments has Boehringer Ingelheim Venture Fund made?
Boehringer Ingelheim Venture Fund has made 106 investments.
-
What has Boehringer Ingelheim Venture Fund invested in?
Boehringer Ingelheim Venture Fund has made numerous investments in companies like EvlaBio, Nuevocor, and HepaRegenix within the Biotechnology and Drug Discovery industries.
-
What has Boehringer Ingelheim Venture Fund invested in recently?
Boehringer Ingelheim Venture Fund's latest investment was on 07-Jul-2025 in EvlaBio, a company within the Biotechnology industry.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
